Geode Capital Management LLC Grows Stock Holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Geode Capital Management LLC grew its position in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 4.5% during the third quarter, Holdings Channel reports. The institutional investor owned 542,523 shares of the medical instruments supplier’s stock after acquiring an additional 23,443 shares during the quarter. Geode Capital Management LLC’s holdings in LeMaitre Vascular were worth $50,403,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of LMAT. NBC Securities Inc. lifted its position in LeMaitre Vascular by 73.2% during the third quarter. NBC Securities Inc. now owns 433 shares of the medical instruments supplier’s stock valued at $40,000 after acquiring an additional 183 shares during the last quarter. USA Financial Formulas purchased a new stake in shares of LeMaitre Vascular during the 3rd quarter valued at $60,000. nVerses Capital LLC lifted its holdings in shares of LeMaitre Vascular by 33.3% during the 2nd quarter. nVerses Capital LLC now owns 800 shares of the medical instruments supplier’s stock valued at $66,000 after purchasing an additional 200 shares during the last quarter. GAMMA Investing LLC boosted its position in shares of LeMaitre Vascular by 34.3% in the 3rd quarter. GAMMA Investing LLC now owns 736 shares of the medical instruments supplier’s stock worth $68,000 after purchasing an additional 188 shares in the last quarter. Finally, Van ECK Associates Corp purchased a new position in LeMaitre Vascular during the 2nd quarter worth $75,000. Hedge funds and other institutional investors own 84.64% of the company’s stock.

LeMaitre Vascular Price Performance

LMAT stock opened at $92.12 on Monday. The company has a market capitalization of $2.07 billion, a P/E ratio of 50.34, a price-to-earnings-growth ratio of 2.47 and a beta of 0.93. LeMaitre Vascular, Inc. has a 12 month low of $52.88 and a 12 month high of $109.58. The firm’s fifty day simple moving average is $97.75 and its 200-day simple moving average is $90.07.

LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings results on Thursday, October 31st. The medical instruments supplier reported $0.49 EPS for the quarter, beating the consensus estimate of $0.44 by $0.05. The company had revenue of $54.82 million for the quarter, compared to analyst estimates of $53.50 million. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. The firm’s revenue was up 15.6% on a year-over-year basis. During the same period in the prior year, the company earned $0.33 earnings per share. As a group, sell-side analysts forecast that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current year.

LeMaitre Vascular Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, December 5th. Investors of record on Thursday, November 21st were given a dividend of $0.16 per share. This represents a $0.64 annualized dividend and a yield of 0.69%. The ex-dividend date was Thursday, November 21st. LeMaitre Vascular’s dividend payout ratio is currently 34.97%.

Insider Buying and Selling at LeMaitre Vascular

In other LeMaitre Vascular news, Director Bridget A. Ross sold 3,750 shares of LeMaitre Vascular stock in a transaction on Friday, November 15th. The shares were sold at an average price of $101.47, for a total value of $380,512.50. Following the completion of the transaction, the director now owns 2,278 shares of the company’s stock, valued at approximately $231,148.66. The trade was a 62.21 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 10.79% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the company. Cantor Fitzgerald assumed coverage on LeMaitre Vascular in a report on Tuesday, October 15th. They issued a “neutral” rating and a $96.00 price target for the company. Barrington Research boosted their target price on shares of LeMaitre Vascular from $92.00 to $93.00 and gave the stock an “outperform” rating in a research report on Friday, November 1st. StockNews.com cut shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Friday, December 13th. Finally, Oppenheimer reissued an “outperform” rating and set a $93.00 price objective (up from $90.00) on shares of LeMaitre Vascular in a report on Friday, November 1st. Three investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $94.57.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.